Morgan Stanley Forecasts Strong Price Appreciation for Medline (NASDAQ:MDLN) Stock

Medline (NASDAQ:MDLN) had its target price boosted by stock analysts at Morgan Stanley from $48.00 to $52.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 17.14% from the company’s current price.

Several other brokerages have also issued reports on MDLN. Wells Fargo & Company upped their target price on shares of Medline from $42.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Barclays started coverage on Medline in a report on Monday, January 12th. They issued an “overweight” rating and a $50.00 price objective for the company. Zacks Research raised Medline to a “hold” rating in a report on Tuesday, January 13th. Wolfe Research initiated coverage on Medline in a research report on Monday, January 12th. They issued an “outperform” rating and a $47.00 target price for the company. Finally, TD Cowen began coverage on shares of Medline in a research report on Monday, January 12th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.50.

Medline Trading Down 3.2%

Shares of MDLN opened at $44.39 on Monday. Medline has a 1-year low of $34.89 and a 1-year high of $50.88. The company has a 50 day moving average of $44.61.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to analyst estimates of $7.52 billion. Medline’s revenue was up 14.8% on a year-over-year basis.

Insider Activity

In related news, Director Charles N. Mills acquired 2,579,310 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the purchase, the director owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their position. The disclosure for this sale is available in the SEC filing.

Institutional Investors Weigh In On Medline

Institutional investors have recently added to or reduced their stakes in the company. Carlyle Group Inc. purchased a new stake in Medline during the 4th quarter valued at $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new stake in shares of Medline during the fourth quarter worth about $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline during the fourth quarter worth about $793,278,000. Morgan Stanley bought a new stake in shares of Medline in the fourth quarter worth about $636,807,000. Finally, Capital Research Global Investors purchased a new position in Medline during the 4th quarter valued at about $620,937,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple analysts raised ratings and price targets this week (Morgan Stanley raised to $52/overweight; TD Cowen maintained Buy and lifted its target to $53), supporting upside thesis on Medline’s growth and margins. Read More.
• Neutral Sentiment: Company-confirmed underwritten offering of 75 million Class A shares has been filed with the SEC; underwriters have a 30-day option to buy an additional 11.25M shares. Medline itself is not selling shares and will receive no proceeds. Read More.
• Neutral Sentiment: Offering is being managed by major banks (Goldman Sachs, Morgan Stanley, BofA, J.P. Morgan); registration filed but not yet effective, so shares cannot trade until effectiveness — timing and pricing uncertainty remains. Read More.
• Negative Sentiment: Selling stockholders are large PE holders (Blackstone, Carlyle, H&F, ADIA) offering 75M shares — the size of the sale implies a meaningful increase in floating supply and potential downward pressure on the stock; investors often view big insider/PE sell-downs as a negative signal. Read More.
• Negative Sentiment: Because Medline receives no proceeds, the transaction does not strengthen the company’s balance sheet — active selling by sponsors can be interpreted as liquidity-taking rather than confidence. Read More.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.